MedTrace Logo

An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma

NCT03061643 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2022-03-08

No results posted yet for this study

Summary

Study of Biweekly Docetaxel plus Androgen-Deprivation Therapy (ADT) in Patients with Previously-Untreated, Metastatic, Prostatic Adenocarcinoma

Conditions

  • Prostatic Neoplasm

Interventions

DRUG

Docetaxel

docetaxel 40 mg/m2 IV every 2 weeks plus ADT

OTHER

Androgen-Deprivation Therapy (ADT)

docetaxel 40 mg/m2 IV every 2 weeks plus ADT

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • SEHOON SEHOON, MD,PhD · SamsungMedicalCenter

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-08
Primary Completion
2022-03-31
Completion
2022-06-30
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03061643 on ClinicalTrials.gov